Company / Cash & Equivalents
AIM ImmunoTech Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.0M
FY2025
5-year range
$1.7M / $32.1M
FY2021-FY2025
Trend
+75.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 4 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -40.0%.
Declined from $5M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -52.0%
- 5-Year CAGR
- -40.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -40.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 75.5% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | +75.5% |
| FY2024 | $1.7M | -68.7% |
| FY2023 | $5.4M | -79.9% |
| FY2022 | $27.1M | -15.7% |
| FY2021 | $32.1M | -16.6% |
| FY2020 | $38.5M | +2519.1% |
| FY2019 | $1.5M | +391.6% |
| FY2018 | $299.0K | -87.6% |
| FY2017 | $2.4M | +0.0% |
| FY2016 | $2.4M | +13.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026